Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Non-GAAP Income Tax Provision by Quarter
Non-GAAP Income Tax Provision ($M) ($M)
Merck Non-GAAP Income Tax Provision: $882M in Q2 2026, down 6.6% from a year earlier.
Latest, Q2 2026
882
Period ended Jun 30, 2026
Change on a year earlier
-6.6%
944 in Q2 2025
History
37 quarters
Since Q4 2016
Sources
31
Documents cited below
Where the Q2 2026 figure comes from
“|| Income Tax Provision (Benefit) | 654 | (219 | ) (3) | (50 | ) (3) | 41 | (3) | (228 | ) | 882”
Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Reported in Form 8-K Table 2a.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Merck Non-GAAP Income Tax Provision ($M), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/nongaap-tax
See every metric in the Merck KPI table. Data updated Oct 26, 2026.